What is MediciNova Interest Expense?
Interest Expense is the amount reported by a company or individual as an expense for borrowed money. MediciNova's interest expense for the
three
months ended in Mar. 2024 was $ 0.00 Mil.
Its interest expense for the trailing twelve months (TTM) ended in Mar. 2024 was $0.00 Mil.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. MediciNova's Operating Income for the
three
months ended in Mar. 2024 was $ -3.14 Mil. MediciNova's Interest Expense for the
three
months ended in Mar. 2024 was $ 0.00 Mil.
MediciNova has no long-term debt (1).
The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
(1) Note: An indication of "no long-term debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
MediciNova Interest Expense Calculation
Interest Expense is the amount reported by a company or individual as an expense for borrowed money.
Interest Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MediciNova (NAS:MNOV) Interest Expense Explanation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
MediciNova's Interest Expense for the
three
months ended in Mar. 2024 was $0.00 Mil. Its
Operating Income
for the
three
months ended in Mar. 2024 was $-3.14 Mil. And its Long-Term Debt & Capital Lease Obligation for the
three
months ended in Mar. 2024 was $0.00 Mil.
MediciNova's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as
| MediciNova had no long-term debt (1). |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Ben Graham prefers companies' interest coverage to be at least 5. MediciNova Inc has enough cash to cover all of its debt. Its financial situation is stable.
MediciNova (MediciNova) Business Description
Traded in Other Exchanges
Address
4275 Executive Square, Suite 300, La Jolla, CA, USA, 92037
MediciNova Inc is a biopharmaceutical company. The company acquires and develops small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Its products portfolio includes therapeutics such as MN-001, MN-166, MN-221 etc. The firm's current strategy is to focus its development activities on therapeutics for neurological disorders and fibrotic diseases.
Executives
| Nicole Lemerond |
director |
3 MURRAY HILL ROAD, SCARSDALE NY 10583 |
| Hideki Nagao |
director |
4350 LA JOLLA VILLAGE DRIVE, SUITE 950, SAN DIEGO CA 92122 |
| Jason J Kruger |
officer: Chief Financial Officer |
4275 EXECUTIVE SQUARE, SUITE 300, LA JOLLA CA 92037 |
| Douglas Paulin |
officer: Chief Financial Officer |
4275 EXECUTIVE SQUARE, SUITE 300, LA JOLLA CA 92037 |
| Gaeta Federico C.a. |
officer: Chief Scientific Officer |
4275 EXECUTIVE SQUARE, SUITE 300, LA JOLLA CA 92037 |
| 3d Investment Partners Pte. Ltd. |
10 percent owner |
250 NORTH BRIDGE ROAD, #13-01 RAFFLES CITY TOWER, SINGAPORE U0 179101 |
| 3d Opportunity Master Fund |
10 percent owner |
C/O MAPLES CORPORATE SERVICES LIMITED, PO BOX 309, UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104 |
| Carolyn Beaver |
director |
3595 JOHN HOPKINS COURT, SAN DIEGO CA 92121 |
| Stepanow Edward C Jr. |
officer: Chief Financial Officer |
4275 EXECUTIVE SQUARE SUITE 300, LA JOLLA CA 92037 |
| Kazuko Matsuda |
officer: Chief Medical Officer |
C/O MEDICINOVA, INC., 4275 EXECUTIVE SQUARE, SUITE 650, LA JOLLA CA 92037 |
| Yuichi Iwaki |
director |
C/O MEDICINOVA, INC., 4275 EXECUTIVE SQUARE, SUITE 650, LA JOLLA CA 92037 |
| Carla Reyes |
officer: Chief Financial Officer |
4275 EXECUTIVE SQUARE, SUITE 300, LA JOLLA CA 92037 |
| Yoshio Ishizaka |
director |
4275 EXECUTIVE SQUARE, SUITE 650, LA JOLLA CA 92037 |
| Yutaka Kobayashi |
director |
4275 EXECUTIVE SQUARE, SUITE 650, LA JOLLA CA 92037 |
| Geoffrey Obrien |
officer: Vice President |
4275 EXECUTIVE SQUARE, SUITE 650, LA JOLLA CA 92037 |
MediciNova (MediciNova) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
MNOV has been successfully added to your 